The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

NCT02220088 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

79

Enrollment

OTHER

Sponsor class

Stopped protocol violation

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: TAI of FOLFOX
DRUG: Sorafenib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]